CLN5 and neoplasm: For example, treatment with 5’-azacitidine and/or FK506 (Shin et al., 2014b; Spiekerkoetter et al., 2013) to activate the Hh response-induced expression of cellular differentiation factors, such as BMPs, in the tumor stroma would induce the luminal-like subtype, which is more manageable with subsequent treatment, including immunotherapy (Massard et al., 2016; Powles et al., 2014).